IMPlications of IMP2 in RNA Biology and Disease
Open accessThe DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index; 134 of the 178 sources its claims cite were checked for support.
Abstract
Insulin-like growth factor 2 mRNA-binding protein 2 (IMP2) is an RNA-binding protein that positively regulates m6A-modified RNAs involved in critical cellular processes such as metabolism, oncogenesis, and immune function. Here, we elucidate facets of IMP2 biology, including several mechanisms of action on RNA, factors that regulate IMP2 expression, its relevant biological target RNAs, its role in normal development and disease, and its potential as a therapeutic target. IMP2 is a multi-level regulator of metabolism, influencing pathways linked to diabetes, obesity, and adipose function. Through genomic amplification and transcriptional overexpression in cancer cells, IMP2 can drive the initiation and progression of multiple cancer types, and high expression is associated with decreased overall survival of patients with cancer. IMP2 influences normal immune function, inflammation, macrophage polarization, and tumor immune evasion. IMP2 has emerged as a promising therapeutic target, particularly for cancers and metabolic diseases.
Overview
CoChat Summary
## TL;DR
This review synthesizes how IMP2/IGF2BP2 acts as an m6A-dependent RNA-binding protein that regulates RNA stability, translation, and sometimes splicing across metabolism, cancer, and immunity. The paper argues that IMP2 is broadly oncogenic and metabolically important, while also highlighting context-specific exceptions such as its tumor-suppressive role in clear cell renal cell carcinoma.
## Key findings
- IMP2 is described as a multi-level regulator of metabolism and disease: it influences diabetes, obesity, adipose function, wound healing, fatty liver disease, cancer, immune function, inflammation, macrophage polarization, and tumor immune evasion.
- In cancer, IGF2BP2 is reported as genomically altered in over 2% of all cancers, with cBioPortal-curated rates including 18% ovarian, 14% cervical, 9% lung, 8% uterine, 5% esophageal/gastric, 4% head and neck, 3% prostate, 3% bladder, 2.8% testicular, 2.8% skin, 2.5% breast, 1.5% colon, 1.3% soft tissue, and 0.8% pancreatic cancers.
- Pan-cancer survival analysis found high IGF2BP2 mRNA associated with worse overall survival in several cancers, including KIRC (HR = 2.1), HNSC (HR = 2.01), SARC (HR = 2.24), PAAD (HR = 3.21), UCEC (HR = 1.94), LUAD (HR = 1.57), LIHC (HR = 1.68), BLCA (HR = 1.54), and KIRP (HR = 2.03); it was associated with better survival in OV (HR = 0.74) and THCA (HR = 0.2).
- In type 2 diabetes, the review reports GWAS links to rs4402960 and rs1470579, and states that pancreatic β-cell-specific IGF2BP2 deletion in mice impaired insulin secretion and reduced compensatory β-cell proliferation under high-fat diet challenge.
## Methods
- This is a review article, not an original experimental study; it synthesizes prior work on IMP2 biology across metabolism, cancer, and immunology.
- The review draws on multiple evidence types cited in the text, including GWAS, pan-cancer database analyses (e.g., GEPIA2, cBioPortal, Kaplan–Meier Plotter), mouse knockout/transgenic models, and cell-based assays such as RIP, RNA pull-down, luciferase reporter assays, RNA stability assays, and xenograft studies.
- The main analysis is narrative integration of these studies to describe IMP2 mechanisms, regulation, target RNAs, and disease relevance.
## Limitations
- The paper explicitly states that it has not been determined whether SNPs in the IMP2 region are causative of T2D phenotypes or whether they share haplotype blocks with other causative elements.
- The review also notes that some reported effects may be context-dependent or partially explained by off-targets, for example where anti-proliferative effects of IMP2 inhibitors were only partially rescued by biallelic IGF2BP2 knockout.
- Evident from the text: because this is a review, many conclusions are drawn from heterogeneous prior studies across different models and tumor types, so direct comparability is limited.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Venn diagram showing the number of overlapping and independent target RNAs regulated by IMP1, IMP2, and IMP3. CLIP-seq and other sequencing data from the POSTAR3 database [10]. Figure created in Python 3.11.0 using the matplotlib_venn library and Adobe Illustrator version 27.9.](https://figures.cochat.ai/paper-figures/da9a332d4ad547b6bb8476cf114f4a75/implications-of-imp2-in-rna-biology-and-disease-figure-2.jpg)


![Figure 5 Genomic and transcriptional changes to IGF2BP2 in cancer. (A) Rate of IGF2BP2 genomic alterations in tumor samples. Data from the cBioPortal curated set of non-redundant studies [77,78,79]. (B) Cancers with decreased expression relative to normal tissue of IGF2BP2 messenger RNA in log2(TPM+1) from tumor (T) relative to normal tissue (N) from the GEPIA2 database [81]. Log fold change between tumor and normal tissue: ACC (−2.66), BRCA (−1.78), and KIRC (−1.95). (C) Cancers with increased expression relative to normal tissue of IGF2BP2 messenger RNA in log2(TPM+1) from tumor (T) relative to normal tissue (N) from the GEPIA2 database [81]. Log fold change between tumor and normal tissue: ESCA (3.74), HNSC (2.85), UCS (2.27), GBM (2.16), PAAD (1.94), OV (1.84), STAD (1.77), READ (1.73), TGCT (1.56), COAD (1.47), SKCM (1.32), LIHC (1.13), LUSC (1.12). See the Abbreviations section for definitions of acronyms. Figure adapted in Adobe Illustrator version 27.9.](https://figures.cochat.ai/paper-figures/4ef2809e4a024799a7cbbd66abeac7bd/implications-of-imp2-in-rna-biology-and-disease-figure-5.jpg)
![Figure 6 Kaplan–Meier analysis of cancers where higher IGF2BP2 expression is significantly associated with decreased (A–I) or increased (J–K) overall survival; data was obtained from Kaplan–Meier Plotter [82,83]. Patients were stratified into high and low IGF2BP2 expression groups based on median expression of IGF2BP2. Only cancers where IGF2BP2 is significantly associated with survival are displayed: KIRC (A), HNCSC (B), SARC (C), PAAD (D), UCEC (E), LUAD (F), LIHC (G), BLCA (H), KIRP (I), THCA (J), and OV (K). Please see the Abbreviations section for definitions of acronyms. Figure adapted in Adobe Illustrator version 27.9.](https://figures.cochat.ai/paper-figures/7b87895f36654739a0ef9ddb9f761ee0/implications-of-imp2-in-rna-biology-and-disease-figure-6.jpg)
Verification
Claims the paper makes
105 Valid · 13 Not valid · 28 Not checked · 9 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Phylogenetically conserved RRM domains on readers are responsible for IMP2 identifying m6A marks on RNA [17,27].”
§ IMPlications of IMP2 in RNA Biology and Disease > 1. Introduction > 1.2. Mechanisms of Action
What the sources say
- Partly supportedcites [17] Jiang, 2021, The Role of m6A Modification in the Biological Functions and Diseases, Signal Transduct. Target. Ther. sourceExperimental — accuracy not yet measured
In “The writers, erasers, and readers of m6A” (page unavailable), the paper identifies IGF2BP2 as an m6A reader and says the IGF2BP family has two RRM domains and binds transcripts containing an m6A motif. It does not say that the RRM domains are responsible for IMP2’s recognition of m6A; its specific account of RRM-mediated recognition concerns a different reader, hnRNP A2/B1. (LLM, conf=0.88)
- Disputedcites [27] Chen, Y., Zhou, Z., Chen, Y., and Chen, D. (2024). Reading the m6A-Encoded Epitranscriptomic Information in Development and Diseases. Cell Biosci., 14. sourceExperimental — accuracy not yet measured
The 'IGF2BP family of m6A readers' section says IGF2BP2 has RRM and KH domains, but assigns m6A-site recognition predominantly to the third and fourth KH domains. It says the RRM domains instead help stabilize IGF2BP–RNA complexes, contrary to the claim that they are responsible for IMP2 identifying m6A marks. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Homozygous IGF2BP2 knockout in lung cells led to a complete halt of proliferation [85].”
§ IMPlications of IMP2 in RNA Biology and Disease > 3. Cancer > 3.5. Lung Cancer
What the sources say
- Disputedcites [85] Chanda, S., Lepikhov, K., Dahlem, C., Schymik, H.S., Hoppstädter, J., Geber, A.-K., Wagner, K., Kessler, S.M., Empting, M., and Kiemer, A.K. (2024). Gene Editing and Small Molecule Inhibitors of the RNA Binding Protein IGF2BP2/IMP2 Show Its Potential as an Anti-Cancer Drug Target. Front. Biosci. (Landmark Ed.), 29. sourceExperimental — accuracy not yet measured
The Discussion (§4) says biallelic IGF2BP2/IMP2 knockout LLC1 lung-cell clones continued to grow: three grew more slowly than a control, while one grew faster. The Abstract says edited A549 lung cells lost the ability to proliferate, but the authors could not generate a biallelic knockout in that line. Thus, the paper does not report a complete halt of proliferation following homozygous knockout in lung cells. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Reader proteins, including IGF2BP proteins and the YTH domain family (e.g., YTHDF1, YTHDF2, YTHDF3, and YTHDC1) proteins, recognize m6A-modified transcripts and modulate their stability and translation [2,26].”
§ IMPlications of IMP2 in RNA Biology and Disease > 1. Introduction > 1.2. Mechanisms of Action
What the sources say
- Supportedcites [2] Huang, 2018, Recognition of RNA N6-Methyladenosine by IGF2BP Proteins Enhances mRNA Stability and Translation, Nat. Cell Biol. source
The Introduction identifies YTH-domain proteins and IGF2BPs as m6A readers and says they regulate mRNA fate through translation, decay, or stabilization. The Discussion likewise reports that IGF2BPs stabilize target mRNAs and facilitate their translation. The source supports the sentence’s broad claim, although it does not individually discuss every YTH protein listed as an example. (LLM, conf=0.91)
- Partly supportedcites [26] Wang, 2014, N6-Methyladenosine-Dependent Regulation of Messenger RNA Stability, Nature sourceExperimental — accuracy not yet measured
The main-text passage labeled Abstract (page unavailable) reports m6A-selective binding by YTHDF1–3, and the Abstract reports that YTHDF2 regulates mRNA decay and moves bound mRNA out of the translatable pool. The copy does not establish the claimed roles for IGF2BP proteins or YTHDC1, or show that YTHDF1 and YTHDF3 modulate stability and translation. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The KH3/4 domains have an anti-parallel pseudo-dimer orientation.”
§ IMPlications of IMP2 in RNA Biology and Disease > 1. Introduction > 1.2. Mechanisms of Action
What the sources say
- Partly supportedcites [15] Zorc, S., Munoz-Tello, P., O’Leary, T., Yu, X., Nag, M., Hansel-Harris, A., Forli, S., Griffin, P.R., Kojetin, D.J., and Roy, R.N. (2024). Structural Insights into IMP2 Dimerization and RNA Binding. bioRxiv. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports that structural analyses of human IGF2BP1 KH3/4 suggest an anti-parallel pseudo-dimer conformation. The claim states this as an established orientation without the paper’s qualification that it is suggested for IGF2BP1; the paper does not establish it for IMP2 KH3/4. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The specificity of target selection among IMP family members is influenced by variations in the KH3/4 domains [6].”
§ IMPlications of IMP2 in RNA Biology and Disease > 1. Introduction > 1.1. IMP Family of RNA-Binding Proteins
What the sources say
- Supportedcites [6] Biswas, 2019, The Structural Basis for RNA Selectivity by the IMP Family of RNA-Binding Proteins, Nat. Commun. source
The Discussion states that mutations in KH-domain variable loops account for differences in RNA sequence specificity between ZBP1 and IMP2. Its account of KH3/4 selection further says that specific variable-loop amino acid mutations mediated the difference in selected RNA targets. The supplied passages do not give page numbers. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
67 more claims · 47 with their cited sources checked
Create a free account to see all 155 claims and to verify the 19 references still open.
- Probably not a substantial claim. 14
- It may state two separate claims as one. 75
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Zhang, 2022, N6-Methyladenosine (m6A) Reader IGF2BP2 Promotes Gastric Cancer Progression via Targeting SIRT1, Bioengineered, 13, 11541, 10.1080/21655979.2022.2068920”
Cited work 10.1080/21655979.2022.2068920 · retracted 2026-10-01 · notice 10.1080/21655979.2026.2729938 · this paper published 2025-03-07
Citations
Cites
1 retracted
Zhang, Z., Xing, Y., Gao, W., Yang, L., Shi, J., Song, W., & Li, T. (2022) · Bioengineered · doi:10.1080/21655979.2022.2068920 · Cited by 34
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“This phenomenon, also known as the Warburg effect, enables cancer cells to rapidly generate energy and biomass precursors even in the presence of oxygen, supporting their accelerated proliferation and survival in harsh tumor microenvironments [76].”
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 5×
“Genomicalterations18%[77–79],overexpressed[81], increasedsurvival[82,83].”
InfluentialIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis
Tang, Z., Kang, B., Li, C., Chen, T., & Zhang, Z. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz430 · Cited by 5,083 · cited 8×
“Genomicalterations18%[77–79],overexpressed[81], increasedsurvival[82,83].”
InfluentialTopology of the human and mouse m6A RNA methylomes revealed by m6A-seq
Dominissini, D., Moshitch-Moshkovitz, S., Schwartz, S., Salmon-Divon, M., Ungar, L., Osenberg, S., Cesarkas, K., Jacob-Hirsch, J., Amariglio, N., Kupiec, M., et al. (2012) · Nature · doi:10.1038/nature11112 · Cited by 4,884 · cited 2×
“This distribution pattern is largely consistent across different cell types and tissues [30,31].”
N6-methyladenosine-dependent regulation of messenger RNA stability
Wang, X., Lu, Z., Gomez, A., Hon, G. C., Yue, Y., Han, D., Fu, Y., Parisien, M., Dai, Q., Jia, G., et al. (2014) · Nature · doi:10.1038/nature12730 · Cited by 4,558 · cited 1×
“Reader proteins, including IGF2BP proteins and the YTH domain family (e.g., YTHDF1, YTHDF2, YTHDF3, and YTHDC1) proteins, recognize m6A-modified tran-Int scripts and modulate their stability and translation [2,26].”
Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop Codons
Meyer, K. D., Saletore, Y., Zumbo, P., Elemento, O., Mason, C. E., & Jaffrey, S. R. (2012) · Cell · doi:10.1016/j.cell.2012.05.003 · Cited by 4,223 · cited 1×
“This distribution pattern is largely consistent across different cell types and tissues [30,31].”
N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO
Jia, G., Fu, Y., Zhao, X., Dai, Q., Zheng, G., Yang, Y., Yi, C., Lindahl, T., Pan, T., Yang, Y.-G., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.687 · Cited by 4,106 · cited 1×
“The m6A modification can be removed by erasers, mainly FTO and ALKBH5 [24,25].”
ALKBH5 Is a Mammalian RNA Demethylase that Impacts RNA Metabolism and Mouse Fertility
Zheng, G., Dahl, J. A., Niu, Y., Fedorcsak, P., Huang, C.-M., Li, C. J., Vågbø, C. B., Shi, Y., Wang, W.-L., Song, S.-H., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.10.015 · Cited by 3,550 · cited 1×
“The m6A modification can be removed by erasers, mainly FTO and ALKBH5 [24,25].”
A METTL3–METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation
Liu, J., Yue, Y., Han, D., Wang, X., Fu, Y., Zhang, L., Jia, G., Yu, M., Lu, Z., Deng, X., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1432 · Cited by 3,433 · cited 1×
“WTAP ensures proper localization and assembly of the METTL3/METTL14 or the METTL16 writer complex within the nuclear speckles [19,20].”
Dynamic RNA Modifications in Gene Expression Regulation
Roundtree, I. A., Evans, M. E., Pan, T., & He, C. (2017) · Cell · doi:10.1016/j.cell.2017.05.045 · Cited by 3,399 · cited 1×
“The distribution patterns of m6A in other RNA types are more varied and often specific to each RNA class [32].”
Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation
Huang, H., Weng, H., Sun, W., Qin, X., Shi, H., Wu, H., Zhao, B. S., Mesquita, A., Liu, C., Yuan, C. L., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0045-z · Cited by 2,997 · cited 5×
“IMP2 is well known for its role as an mRNA-binding protein that physically associates with its mRNA targets in an N 6 -methyladenosine (m6A)- dependent manner, leading to enhanced stability of target RNA and increased protein translation (Figure 1) [2].”
InfluentialTranscriptome-wide Identification of RNA-Binding Protein and MicroRNA Target Sites by PAR-CLIP
Hafner, M., Landthaler, M., Burger, L., Khorshid, M., Hausser, J., Berninger, P., Rothballer, A., Ascano, M., Jungkamp, A.-C., Munschauer, M., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.009 · Cited by 2,873 · cited 3×
“IMP proteins can bind the mRNA of other IMP proteins, suggesting an additional layer of interaction between family members [7].”
InfluentialGenome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels
Saxena, R., Voight, B. F., Lyssenko, V., Burtt, N. P., de Bakker, P. I. W., Chen, H., Roix, J. J., Kathiresan, S., Hirschhorn, J. N., Daly, M. J., et al. (2007) · Science · doi:10.1126/science.1142358 · Cited by 2,843
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., Erdos, M. R., Stringham, H. M., Chines, P. S., Jackson, A. U., et al. (2007) · Science · doi:10.1126/science.1142382 · Cited by 2,753
Reading, writing and erasing mRNA methylation
Zaccara, S., Ries, R. J., & Jaffrey, S. R. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0168-5 · Cited by 2,597 · cited 2×
“This modification is a dynamic and reversible process, regulated by the coordinated action of writers, erasers, and readers [18].”
Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase
Ping, X.-L., Sun, B.-F., Wang, L., Xiao, W., Yang, X., Wang, W.-J., Adhikari, S., Shi, Y., Lv, Y., Chen, Y.-S., et al. (2014) · Cell Research · doi:10.1038/cr.2014.3 · Cited by 2,375 · cited 1×
“WTAP ensures proper localization and assembly of the METTL3/METTL14 or the METTL16 writer complex within the nuclear speckles [19,20].”
The role of m6A modification in the biological functions and diseases
Jiang, X., Liu, B., Nie, Z., Duan, L., Xiong, Q., Jin, Z., Yang, C., & Chen, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00450-x · Cited by 2,335 · cited 2×
“The interaction between IMP2 and its target RNA transcripts depends on m6A modifications [16]. m6A (N6-methyladenosine) is a prevalent post-transcriptional modification found in mRNA and non-coding RNA in eukaryotic cells [17].”
Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes
Zeggini, E., Weedon, M. N., Lindgren, C. M., Frayling, T. M., Elliott, K. S., Lango, H., Timpson, N. J., Perry, J. R. B., Rayner, N. W., Freathy, R. M., et al. (2007) · Science · doi:10.1126/science.1142364 · Cited by 2,194 · cited 1×
“The association between IMP2 and T2D was first identified through genome-wide association studies (GWAS) in 2007, with three independent research groups demonstrating a strong link between genetic variants in the IGF2BP2 gene and T2D risk [69–71].”
Meyers, R. M., Bryan, J. G., McFarland, J. M., Weir, B. A., Sizemore, A. E., Xu, H., Dharia, N. V., Montgomery, P. G., Cowley, G. S., Pantel, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3984 · Cited by 1,952
m6A RNA methylation promotes XIST-mediated transcriptional repression
Patil, D. P., Chen, C.-K., Pickering, B. F., Chow, A., Jackson, C., Guttman, M., & Jaffrey, S. R. (2016) · Nature · doi:10.1038/nature19342 · Cited by 1,747 · cited 1×
“Additional components such as RBM15, KIAA1429, and ZC3H13 have been identified as part of the larger m6A writer complex [21–23].”
Schwartz, S., Mumbach, M. R., Jovanovic, M., Wang, T., Maciag, K., Bushkin, G. G., Mertins, P., Ter-Ovanesyan, D., Habib, N., Cacchiarelli, D., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.048 · Cited by 1,216
Circularization of mRNA by Eukaryotic Translation Initiation Factors
Wells, S. E., Hillner, P. E., Vale, R. D., & Sachs, A. B. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80122-7 · Cited by 981 · cited 1×
“This circularization is facilitated by the 3 ′ UTR and enhances translation efficiency by bringing the 5 ′ and 3 ′ ends of the mRNA into proximity, allowing for the regulation of translation through 3 ′ UTR binding sites [35].”
Zc3h13 Regulates Nuclear RNA m6A Methylation and Mouse Embryonic Stem Cell Self-Renewal
Wen, J., Lv, R., Ma, H., Shen, H., He, C., Wang, J., Jiao, F., Liu, H., Yang, P., Tan, L., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.02.015 · Cited by 941 · cited 1×
“Additional components such as RBM15, KIAA1429, and ZC3H13 have been identified as part of the larger m6A writer complex [21–23].”
de Bruijn, I., Kundra, R., Mastrogiacomo, B., Tran, T. N., Sikina, L., Mazor, T., Li, X., Ochoa, A., Zhao, G., Lai, B., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0816 · Cited by 886 · cited 5×
“Genomicalterations18%[77–79],overexpressed[81], increasedsurvival[82,83].”
InfluentialMETTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma
Li, T., Hu, P.-S., Zuo, Z., Lin, J.-F., Li, X., Wu, Q.-N., Chen, Z.-H., Zeng, Z.-L., Wang, F., Zheng, J., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1038-7 · Cited by 799
Nielsen, J., Christiansen, J., Lykke-Andersen, J., Johnsen, A. H., Wewer, U. M., & Nielsen, F. C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1262 · Cited by 721 · cited 3×
“References [4,13,16,28,36–40,”
Li, B., Zhu, L., Lu, C., Wang, C., Wang, H., Jin, H., Ma, X., Cheng, Z., Yu, C., Wang, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20527-z · Cited by 697 · cited 1×
“Lung cancer, specifically NSCLC, represents another example of IMP2’s involvement in tumor progression and immune regulation [123].”
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
Wolfe, A. L., Singh, K., Zhong, Y., Drewe, P., Rajasekhar, V. K., Sanghvi, V. R., Mavrakis, K. J., Jiang, M., Roderick, J. E., Van der Meulen, J., et al. (2014) · Nature · doi:10.1038/nature13485 · Cited by 635 · cited 1×
“IMP2 directly binds to the eIF4A protein, a member of the eIF4F translation initiation complex that acts as the helicase responsible for unwinding RNA secondary and tertiary structures to allow the ribosome to more efficiently translate mRNA into protein [33,34].”
Self-citationDescombes, P., Chojkier, M., Lichtsteiner, S., Falvey, E., & Schibler, U. (1990) · Genes & Development · doi:10.1101/gad.4.9.1541 · Cited by 575
LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer
Wang, Y., Lu, J.-H., Wu, Q.-N., Jin, Y., Wang, D.-S., Chen, Y.-X., Liu, J., Luo, X.-J., Meng, Q., Pu, H.-Y., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1105-0 · Cited by 507 · cited 1×
“LINRIS is another lncRNA associated with CRC [53].”
Győrffy, B. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100625 · Cited by 464 · cited 7×
“Genomicalterations18%[77–79],overexpressed[81], increasedsurvival[82,83].”
InfluentialImp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells
Janiszewska, M., Suvà, M. L., Riggi, N., Houtkooper, R. H., Auwerx, J., Clément-Schatlo, V., Radovanovic, I., Rheinbay, E., Provero, P., & Stamenkovic, I. (2012) · Genes & Development · doi:10.1101/gad.188292.112 · Cited by 452
m6A-dependent glycolysis enhances colorectal cancer progression
Shen, C., Xuan, B., Yan, T., Ma, Y., Xu, P., Tian, X., Zhang, X., Cao, Y., Ma, D., Zhu, X., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01190-w · Cited by 437 · cited 6×
“In METTL3-knockout cells, IMP2 binding to HK2 and GLUT1 mRNAs is substantially impaired [16].”
InfluentialMechanisms of liver fibrosis and its role in liver cancer
Dhar, D., Baglieri, J., Kisseleva, T., & Brenner, D. A. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370219898141 · Cited by 429 · cited 1×
“Liver fibrosis is a wound healing response whose signaling is entwined with hepato-cellular carcinoma [114].”
RNA-binding proteins in tumor progression
Qin, H., Ni, H., Liu, Y., Yuan, Y., Xi, T., Li, X., & Zheng, L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00927-w · Cited by 375 · cited 1×
“RNA-binding proteins (RBPs) are a large and diverse group of proteins that help regulate essential processes encompassing mRNA transport, localization, alternative splicing, translation, and RNA stability [1].”
IGF2BP2 regulates DANCR by serving as an N6-methyladenosine reader
Hu, X., Peng, W.-X., Zhou, H., Jiang, J., Zhou, X., Huang, D., Mo, Y.-Y., & Yang, L. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0461-z · Cited by 363
Győrffy, B. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16257 · Cited by 361 · cited 7×
“Genomicalterations18%[77–79],overexpressed[81], increasedsurvival[82,83].”
InfluentialWeng, H., Huang, F., Yu, Z., Chen, Z., Prince, E., Kang, Y., Zhou, K., Li, W., Hu, J., Fu, C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.004 · Cited by 336 · cited 4×
“In acute myeloid leukemia (AML), IMP2 stabilizes key mRNAs, including MYC , GPT2 , and SLC1A5 , that are essential for glutamine uptake and metabolism, fueling the TCA cycle and supporting AML cell proliferation and survival [113].”
InfluentialDegrauwe, N., Suvà, M.-L., Janiszewska, M., Riggi, N., & Stamenkovic, I. (2016) · Genes & Development · doi:10.1101/gad.287540.116 · Cited by 324 · cited 1×
“While IMP1 and IMP3 are typically expressed at low levels in adult tissues, IMP2 is retained in several adult mouse organs [9].”
mRNA helicases: the tacticians of translational control
Parsyan, A., Svitkin, Y., Shahbazian, D., Gkogkas, C., Lasko, P., Merrick, W. C., & Sonenberg, N. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3083 · Cited by 323 · cited 1×
“IMP2 directly binds to the eIF4A protein, a member of the eIF4F translation initiation complex that acts as the helicase responsible for unwinding RNA secondary and tertiary structures to allow the ribosome to more efficiently translate mRNA into protein [33,34].”
Gong, C., Li, Z., Ramanujan, K., Clay, I., Zhang, Y., Lemire-Brachat, S., & Glass, D. J. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.05.009 · Cited by 305 · cited 1×
“Conversely, IGF2BP2 mRNA is negatively regulated by lncMyoD , which binds to IMP2 and prevents IMP2 from acting upon its targets to increase translation, allowing for exit out of the cell cycle and skeletal muscle differentiation [48,54].”
Hansen, T. V. O., Hammer, N. A., Nielsen, J., Madsen, M., Dalbaeck, C., Wewer, U. M., Christiansen, J., & Nielsen, F. C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.10.4448-4464.2004 · Cited by 251 · cited 2×
“IMP1 KO mice display severe growth retardation, elevated perinatal mortality, and significant defects in intestinal development [11].”
Hagenbeek, T. J., Zbieg, J. R., Hafner, M., Mroue, R., Lacap, J. A., Sodir, N. M., Noland, C. L., Afghani, S., Kishore, A., Bhat, K. P., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00577-0 · Cited by 215
mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry
Dai, N., Rapley, J., Angel, M., Yanik, M. F., Blower, M. D., & Avruch, J. (2011) · Genes & Development · doi:10.1101/gad.2042311 · Cited by 208 · cited 4×
“Alternatively, when IMP2 binds to the 5 ′ UTR, as in the case of IGF2 mRNA, it facilitates 5 ′ cap-independent translation through an internal ribosomal entry site (IRES) [36].”
InfluentialXu, X., Yu, Y., Zong, K., Lv, P., & Gu, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1470-y · Cited by 203
Zhang, J.-Y., Chan, E. K. L., Peng, X.-X., & Tan, E. M. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.7.1101 · Cited by 202 · cited 1×
“…was nearly identical to the p62 protein but included an additional insertion of 43 amino acids, representing a second splice isoform of IGF2BP2 [5]. target for immuno-oncology, while pharmacological inhibition of IMP2 is emerging as a strategy to mitigate the myriad e ff ects of this versatile…”
HMGA2 as a Critical Regulator in Cancer Development
Mansoori, B., Mohammadi, A., Ditzel, H. J., Duijf, P. H. G., Khaze, V., Gjerstorff, M. F., & Baradaran, B. (2021) · Genes · doi:10.3390/genes12020269 · Cited by 201 · cited 3×
“HMGA2 is highly expressed during development, where it plays a critical role in regulating IMP2 expression, particularly through binding to AT-rich regions on the first intron of IGF2BP2 in co-operation with NF-kB [43].”
Zhao, W., Zhang, S., Zhu, Y., Xi, X., Bao, P., Ma, Z., Kapral, T. H., Chen, S., Zagrovic, B., Yang, Y. T., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab702 · Cited by 200
Huang, J., Sun, W., Wang, Z., Lv, C., Zhang, T., Zhang, D., Dong, W., Shao, L., He, L., Ji, X., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02254-z · Cited by 198 · cited 3×
“These findings highlight the critical role of the FTO/APOE/IMP2 axis in regulating glycolysis in PTC, with IMP2 acting as a key stabilizer of APOE mRNA to enhance glycolysis and promote tumor growth [102].”
InfluentialMETTL3 counteracts premature aging via m6A-dependent stabilization of MIS12 mRNA
Wu, Z., Shi, Y., Lu, M., Song, M., Yu, Z., Wang, J., Wang, S., Ren, J., Yang, Y.-G., Liu, G.-H., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa816 · Cited by 189
Dai, N., Zhao, L., Wrighting, D., Krämer, D., Majithia, A., Wang, Y., Cracan, V., Borges-Rivera, D., Mootha, V. K., Nahrendorf, M., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.03.006 · Cited by 188 · cited 2×
“References [4,13,16,28,36–40,”
Hu, C., Liu, T., Han, C., Xuan, Y., Jiang, D., Sun, Y., Zhang, X., Zhang, W., Xu, Y., Liu, Y., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.67770 · Cited by 159
IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism
Pu, J., Wang, J., Qin, Z., Wang, A., Zhang, Y., Wu, X., Wu, Y., Li, W., Xu, Z., Lu, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.578816 · Cited by 156
Peng, F., Xu, J., Cui, B., Liang, Q., Zeng, S., He, B., Zou, H., Li, M., Zhao, H., Meng, Y., et al. (2020) · Cell Research · doi:10.1038/s41422-020-00397-2 · Cited by 150
Wang, X., Ji, Y., Feng, P., Liu, R., Li, G., Zheng, J., Xue, Y., Wei, Y., Ji, C., Chen, D., et al. (2021) · Advanced Science · doi:10.1002/advs.202100209 · Cited by 147 · cited 2×
“Beyond driving autoimmune inflammation, IMP2 plays a central, context-dependent role in macrophage polarization [120].”
Degrauwe, N., Schlumpf, T. B., Janiszewska, M., Martin, P., Cauderay, A., Provero, P., Riggi, N., Suvà, M.-L., Paro, R., & Stamenkovic, I. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.086 · Cited by 136 · cited 1×
“IMP1, IMP2, and IMP3 proteins play crucial roles during embryogenesis, where they regulate metabolism and stem cell renewal [8].”
Yu, D., Pan, M., Li, Y., Lu, T., Wang, Z., Liu, C., & Hu, G. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02212-1 · Cited by 120
Lu, S., Han, L., Hu, X., Sun, T., Xu, D., Li, Y., Chen, Q., Yao, W., He, M., Wang, Z., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01204-0 · Cited by 116 · cited 3×
“This interaction boosts the activity of OLA, leading to increased ATP hydrolysis and glycolysis [97].”
InfluentialThe Diverse Functions of IMP2/IGF2BP2 in Metabolism
Dai, N. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.05.007 · Cited by 114 · cited 2×
“This aligns with human studies showing that individuals with T2D-associated IGF2BP2 variants have reduced insulin secretion [75].”
Liu, F.-Y., Zhou, S.-J., Deng, Y.-L., Zhang, Z.-Y., Zhang, E.-L., Wu, Z.-B., Huang, Z.-Y., & Chen, X.-P. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.46 · Cited by 114
Ye, S., Song, W., Xu, X., Zhao, X., & Yang, L. (2016) · FEBS Letters · doi:10.1002/1873-3468.12205 · Cited by 108 · cited 1×
“There are several known targets of IMP2 that are important for the progression of colorectal cancer, including MYC and RAF1 [86,87].”
Dai, N., Ji, F., Wright, J., Minichiello, L., Sadreyev, R., & Avruch, J. (2017) · eLife · doi:10.7554/elife.27155 · Cited by 103
Haderk, F., Chou, Y.-T., Cech, L., Fernández-Méndez, C., Yu, J., Olivas, V., Meraz, I. M., Barbosa Rabago, D., Kerr, D. L., Gomez, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47423-0 · Cited by 103
Cleynen, I., Brants, J. R., Peeters, K., Deckers, R., Debiec-Rychter, M., Sciot, R., Van de Ven, W. J. M., & Petit, M. M. R. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0331 · Cited by 92
Zhou, Y., Yan, J., Huang, H., Liu, L., Ren, L., Hu, J., Jiang, X., Zheng, Y., Xu, L., Zhong, F., et al. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06509-9 · Cited by 92 · cited 2×
“IMP2 is highly expressed in liver fibrosis and activated hepatic stellate cells (HSCs), where it plays a pivotal role by modulating glycolytic metabolism [104].”
IGF2BP2 promotes the progression of colorectal cancer through a YAP‐dependent mechanism
Cui, J., Tian, J., Wang, W., He, T., Li, X., Gu, C., Wang, L., Wu, J., & Shang, A. (2021) · Cancer Science · doi:10.1111/cas.15083 · Cited by 90 · cited 1×
“For example, IMP2 binds near an m6A motif on the Yes-associated protein ( YAP ) mRNA [89].”
Bechara, R., Amatya, N., Bailey, R. D., Li, Y., Aggor, F. E. Y., Li, D.-D., Jawale, C. V., Coleman, B. M., Dai, N., Gokhale, N. S., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abd1287 · Cited by 89 · cited 1×
“Similarly, in AGN, IMP2 stabilized mRNAs encoding the transcription factors C/EBP β and C/EBP δ , driving the expression of inflammatory genes such as Lipocalin-2 (LCN2) [119].”
The Structural Basis for RNA Selectivity by the IMP Family of RNA-Binding Proteins
Biswas, J., Patel, V. L., Bhaskar, V., Chao, J. A., Singer, R. H., & Eliscovich, C. (2019) · Nature Communications · doi:10.1038/s41467-019-12193-7 · Cited by 84 · cited 7×
“Despite structural similarities, IMP2 binds to a distinct set of RNA targets and consensus binding motifs, as compared to IMP1 or IMP3 [6].”
InfluentialHao, C., Xu, C., Zhao, X., Luo, J., Wang, G., Zhao, L., Ge, X., & Ge, X. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01772-y · Cited by 81
The biological function of IGF2BPs and their role in tumorigenesis
Du, Q., Zhu, Z., & Pei, D. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01148-9 · Cited by 74 · cited 1×
“IMP2 is known by several other names: VICKZ2, P62, and KH domain-containing protein overexpressed in cancer protein (KOC) [2,3].”
Huang, R.-S., Zheng, Y.-L., Li, C., Ding, C., Xu, C., & Zhao, J. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.03.005 · Cited by 73
Kim, H.-Y., Ha Thi, H. T., & Hong, S. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.039 · Cited by 72 · cited 2×
“Specifically, IMP2 has been shown to promote the degradation of mRNAs, such as progesterone receptor ( PR ) and Frizzled class receptor 8 ( FZD8 ), by recruiting the CCR4-NOT deadenylase complex through interaction with its scaffold protein CNOT1 [38,39].”
First Small-Molecule Inhibitors Targeting the RNA-Binding Protein IGF2BP2/IMP2 for Cancer Therapy
Dahlem, C., Abuhaliema, A., Kessler, S. M., Kröhler, T., Zoller, B. G. E., Chanda, S., Wu, Y., Both, S., Müller, F., Lepikhov, K., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00833 · Cited by 70 · cited 2×
“Screening of compound libraries led to the identification of IMP2 inhibitors, which bound IMP2 by STD/NMR [126].”
Brants, J. R., Ayoubi, T. A. Y., Chada, K., Marchal, K., Van de Ven, W. J. M., & Petit, M. M. R. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.05.075 · Cited by 68
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L. (2024) · Current Oncology · doi:10.3390/curroncol31040150 · Cited by 68 · cited 1×
“YAP is a positive regulator of HER2 expression, which acts to control enzymes critical for post-translational modifications and is often reactivated as a mechanism of resistance to inhibition of KRAS and other MAPK pathway proteins [90–94].”
Self-citationElcheva, I. A., Gowda, C. P., Bogush, D., Gornostaeva, S., Fakhardo, A., Sheth, N., Kokolus, K. M., Sharma, A., Dovat, S., Uzun, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1224516 · Cited by 66 · cited 2×
“In melanoma, IMP2, as part of the IMP family, plays a crucial role in regulating immune responses by binding to and stabilizing mRNAs coding for interferon-stimulated genes (ISGs) and major histocompatibility complex (MHC) class I molecules [125].”
Shen, H., Zhu, H., Chen, Y., Shen, Z., Qiu, W., Qian, C., & Zhang, J. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03571-5 · Cited by 66
Overexpression of the IGF2-mRNA binding protein p62 in transgenic mice induces a steatotic phenotype
Tybl, E., Shi, F.-D., Kessler, S. M., Tierling, S., Walter, J., Bohle, R. M., Wieland, S., Zhang, J., Tan, E. M., & Kiemer, A. K. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.034 · Cited by 65 · cited 1×
“Transgenic overexpression of IMP2 in mice using the liver-specific promoter LAP caused improved glucose tolerance, a buildup of liver fat, and cirrhosis [65–67].”
The HMGA2-IMP2 Pathway Promotes Granulosa Cell Proliferation in Polycystic Ovary Syndrome
Li, M., Zhao, H., Zhao, S.-G., Wei, D.-M., Zhao, Y.-R., Huang, T., Muhammad, T., Yan, L., Gao, F., Li, L., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00544 · Cited by 64
Ye, M., Chen, J., Lu, F., Zhao, M., Wu, S., Hu, C., Yu, P., Kan, J., Bai, J., Tian, Y., et al. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01100-9 · Cited by 64 · cited 1×
“RNA-seq and MeRIP-seq identified HK2 as a downstream target of IMP2, and MeRIP confirmed the interaction between m6A and HK2 mRNA [96].”
Ma, Y., Shi, B., Guo, J., Liu, J., Yang, X., Xin, R., Shi, Y., Zhang, D., Lu, G., Jia, C., et al. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab023 · Cited by 63
Oliveira-Mateos, C., Sánchez‐Castillo, A., Soler, M., Obiols-Guardia, A., Piñeyro, D., Boqué-Sastre, R., Calleja-Cervantes, M. E., de Moura, M. C., Martínez‐Cardús, A., Rubio, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11910-6 · Cited by 62
Li, Z., Zhang, Y., Ramanujan, K., Ma, Y., Kirsch, D. G., & Glass, D. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3947 · Cited by 61
Rao, P., Wang, H., Fang, H., Gao, Q., Zhang, J., Song, M., Zhou, Y., Wang, Y., & Wang, W. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13060574 · Cited by 61 · cited 1×
“Individuals in a Han Chinese population carrying the TT genotype at rs4402960 had a higher risk of developing T2D compared to those with TG or GG genotypes, and CC carriers at rs1470579 were more susceptible to T2D than A allele carriers [72].”
Regué, L., Zhao, L., Ji, F., Wang, H., Avruch, J., & Dai, N. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101209 · Cited by 60 · cited 7×
“Mice with pancreatic β -cell-specific deletion of IMP2 ( β IMP2KO) exhibited impaired insulin secretion and reduced compensatory β -cell proliferation when challenged with a high-fat diet (HFD) [68].”
InfluentialRole of the RNA-Binding Protein IMP-2 in Muscle Cell Motility
Boudoukha, S., Cuvellier, S., & Polesskaya, A. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00665-10 · Cited by 58
Liu, H., Qin, S., Liu, C., Jiang, L., Li, C., Yang, J., Zhang, S., Yan, Z., Liu, X., Yang, J., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00674-y · Cited by 58 · cited 9×
“In GBM, IMP2 recognizes the m6A modification site on the long non-coding RNA CASC9 , enhancing its stability [13].”
InfluentialSuo, M., Rommelfanger, M. K., Chen, Y., Amro, E. M., Han, B., Chen, Z., Szafranski, K., Chakkarappan, S. R., Boehm, B. O., MacLean, A. L., et al. (2022) · Blood · doi:10.1182/blood.2021012197 · Cited by 57 · cited 1×
“Moreover, IMP2 expression declined as hematopoietic progenitor cells (HPCs) aged, and similarly, germline knockout of IMP2 in mice led to diminished growth and repopulation capacity in young HPCs, along with decreased markers of stemness—both phenotypes associated with HPC aging [41].”
Peng, T., Liu, M., Hu, L., Guo, D., Wang, D., Qi, B., Ren, G., Hu, C., Zhang, F., Chun, H. J., et al. (2022) · Biology Direct · doi:10.1186/s13062-022-00346-6 · Cited by 57 · cited 3×
“However, loss of this interaction leads to diabetic cardiac fi brosis [48].”
Wolfe, A. L., Zhou, Q., Toska, E., Galeas, J., Ku, A. A., Koche, R. P., Bandyopadhyay, S., Scaltriti, M., Lebrilla, C. B., McCormick, F. P., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103592118 · Cited by 57 · cited 1×
“YAP is a positive regulator of HER2 expression, which acts to control enzymes critical for post-translational modifications and is often reactivated as a mechanism of resistance to inhibition of KRAS and other MAPK pathway proteins [90–94].”
Self-citationLu, W., Yang, X., Zhong, W., Chen, G., Guo, X., Ye, Q., Xu, Y., Qi, Z., Ye, Y., Zhang, J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci174847 · Cited by 57
Li, Y., Wang, Z., Gao, P., Cao, D., Dong, R., Zhu, M., Fei, Y., Zuo, X., & Cai, J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05498-9 · Cited by 55 · cited 1×
“…tumor growth and increased immune cell infiltration, highlighting the role of IMP2 in immune activation in NSCLC. Gastric tumors exploit the ability of IMP2 to stabilize PD-L1 mRNA to facilitate immune escape, a process mediated through its interaction with the circular RNA cir-cRHBDD1 [124].”
Loss of Stromal IMP1 Promotes a Tumorigenic Microenvironment in the Colon
Hamilton, K. E., Chatterji, P., Lundsmith, E. T., Andres, S. F., Giroux, V., Hicks, P. D., Noubissi, F. K., Spiegelman, V. S., & Rustgi, A. K. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0224 · Cited by 52 · cited 1×
“In contrast to the oncogenic role of IMP3, deletion of IMP1 in stromal cells in the same treatment model leads to increased tumor burden, suggesting an alternative tumor-suppressive function in certain tissue contexts [14].”
Xia, T., Dai, X., Sang, M., Zhang, X., Xu, F., Wu, J., Shi, L., Wei, J., & Ding, Q. (2024) · Advanced Science · doi:10.1002/advs.202305142 · Cited by 52 · cited 2×
“This hypomethylation is a distinguishing feature of TNBC compared to other breast cancer subtypes [42].”
Schaeffer, V., Hansen, K. M., Morris, D. R., LeBoeuf, R. C., & Abrass, C. K. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00185.2012 · Cited by 50
Liu, T., Hu, C., Han, C., Mao, S., Zhang, W., Xu, Y., Sun, Y., Jiang, D., Zhang, X.-Y., Zhang, J., et al. (2023) · Biology Direct · doi:10.1186/s13062-023-00373-x · Cited by 49
Zhao, F., Wu, L., Wang, Q., Zhao, X., Chen, T., Yin, C., Yan, L., & Yang, X. (2022) · Cell Proliferation · doi:10.1111/cpr.13216 · Cited by 48 · cited 5×
“For instance, overexpression of IGF2BP2 cDNA caused a significant shift in the splice isoform ratio of IMP2 target NFIC [37].”
InfluentialWang, J., Zhu, M., Zhu, J., Li, J., Zhu, X., Wang, K., Shen, K., Yang, K., Ni, X., Liu, X., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01707-4 · Cited by 41 · cited 1×
“HES1 knockdown reduces GLUT1 levels, aerobic glycolysis, and CRC proliferation, while IMP2 is required for HES1-mediated stabilization of m6A-modified GLUT1 mRNA, underscoring the importance of the HES1-IMP2 axis in CRC progression [95].”
Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas
Hiramatsu, K., Yoshino, K., Serada, S., Yoshihara, K., Hori, Y., Fujimoto, M., Matsuzaki, S., Egawa-Takata, T., Kobayashi, E., Ueda, Y., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.27 · Cited by 40 · cited 2×
“Flow cytometry demonstrated that the knockdown of IMP2 led to an increase in G0/G1 phase compared to the S phase, underscoring the importance of IMP2 in regulating cell proliferation in ovarian cancer [107].”
Wu, X., Lu, R., Wang, L., Wang, Y., Dai, Y., Wang, C., Yang, Y., Guo, F., Xue, J., & Yang, D. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27079 · Cited by 40 · cited 1×
“The long noncoding RNA HOTAIR also impacts CRC progression by regulating IMP2 expression [52].”
Lin, Z., Lv, D., Liao, X., Peng, R., Liu, H., Wu, T., Wu, K., Sun, Y., & Zhang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1226962 · Cited by 39 · cited 2×
“In vivo experiments using a mouse model of DKD further supported these findings, revealing that manipulating circUBXN7 expression affected macrophage behavior and contributed to disease progression [121].”
Xing, M., Li, P., Wang, X., Li, J., Shi, J., Qin, J., Zhang, X., Ma, Y., Francia, G., & Zhang, J.-Y. (2019) · Cancers · doi:10.3390/cancers12010007 · Cited by 39 · cited 1×
“While the direct mechanism is unknown, IMP2 overexpression activates the Wnt pathway, resulting in the relocalization of β -catenin from the cytoplasm to the nucleus, as well as the expression of Wnt3a, a Wnt ligand [105].”
Loss of Hilnc prevents diet-induced hepatic steatosis through binding of IGF2BP2
Jiang, Y., Peng, J., Song, J., He, J., Jiang, M., Wang, J., Ma, L., Wang, Y., Lin, M., Wu, H., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00488-3 · Cited by 39
RHPN1-AS1 Drives the Progression of Hepatocellular Carcinoma via Regulating miR-596/IGF2BP2 Axis
Fen, H., Hongmin, Z., Wei, W., Chao, Y., Yang, Y., Bei, L., & Zhihua, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612825666191105104549 · Cited by 38
HMGB2 regulates satellite-cell-mediated skeletal muscle regeneration through IGF2BP2
Zhou, X., Li, M., Huang, H., Chen, K., Yuan, Z., Zhang, Y., Nie, Y., Chen, H., Zhang, X., Chen, L., et al. (2016) · Journal of Cell Science · doi:10.1242/jcs.189944 · Cited by 38
Autoimmune Response to IGF 2 mRNA‐Binding Protein 2 (IMP 2/p62) in Breast Cancer
Liu, W., Li, Y., Wang, B., Dai, L., Qian, W., & Zhang, J. ‐. (2015) · Scandinavian Journal of Immunology · doi:10.1111/sji.12285 · Cited by 37 · cited 1×
“Through ELISA, IMP2 has been shown to trigger an autoimmune response in breast cancer, as evidenced by the presence of autoantibodies [99], suggesting the potential of screening for IMP2 as a biomarker for breast cancer.”
p62/IMP2 stimulates cell migration and reduces cell adhesion in breast cancer
Li, Y., Francia, G., & Zhang, J.-Y. (2015) · Oncotarget · doi:10.18632/oncotarget.5328 · Cited by 36 · cited 2×
“In MDA-MB-468 cells, overexpression of IMP2 increased MYC mRNA and protein, whereas IMP2 knockout decreased both MYC mRNA and protein levels [112].”
Yang, Y., Liu, X., Cheng, L., Li, L., Wei, Z., Wang, Z., Han, G., Wan, X., Wang, Z., Zhang, J., et al. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s232795 · Cited by 35
Evaluation of the Association of IGF2BP2 Variants With Type 2 Diabetes in French Caucasians
Duesing, K., Fatemifar, G., Charpentier, G., Marre, M., Tichet, J., Hercberg, S., Balkau, B., Froguel, P., & Gibson, F. (2008) · Diabetes · doi:10.2337/db07-1789 · Cited by 35 · cited 1×
“Research conducted in a French Caucasian population did not find a significant association between rs4402960 or rs1470579 and T2D risk [73].”
Zhu, L., Huang, Z., Qiu, J., Shi, Y., Zuo, D., Qiu, Z., He, W., Niu, Y., Yuan, Y., & Li, B. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03134-4 · Cited by 34
Liu, W., Li, Z., Xu, W., Wang, Q., & Yang, S. (2013) · Scandinavian Journal of Immunology · doi:10.1111/sji.12032 · Cited by 33 · cited 1×
“Autoantibody responses to IMP2 epitopes expressed in colon cancer were observed at a higher frequency compared to non-cancerous samples, underscoring the importance of IMP2 overexpression as a marker for malignancy [88].”
Posttranscriptional regulation of colonic epithelial repair by RNA binding protein IMP1/IGF2BP1
Chatterji, P., Williams, P. A., Whelan, K. A., Samper, F. C., Andres, S. F., Simon, L. A., Parham, L. R., Mizuno, R., Lundsmith, E. T., Lee, D. S., et al. (2019) · The EMBO Reports · doi:10.15252/embr.201847074 · Cited by 32
CCN6 regulates IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of the breast
McMullen, E. R., Gonzalez, M. E., Skala, S. L., Tran, M., Thomas, D., Djomehri, S. I., Burman, B., Kidwell, K. M., & Kleer, C. G. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4960-2 · Cited by 31 · cited 1×
“In metaplastic breast carcinoma (MBC), CCN6 acts as an upstream regulator of IGF2BP2 [100].”
Rozengurt, E., & Eibl, G. (2021) · Cancers · doi:10.3390/cancers13205126 · Cited by 30
Jing, F., Zhao, J., Jing, X., & Lei, G. (2020) · Cell Biology International · doi:10.1002/cbin.11392 · Cited by 28 · cited 1×
“Similarly, Airn protects against diabetic nephropathy (DN) by interacting with IGF2BP2 mRNA to promote the translation of proteins like IGF2 and LAMB2, maintaining podocyte viability and glomerular barrier function [49].”
Wang, T., Li, X., Tao, Y., Wang, X., Li, L., & Liu, J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05463-6 · Cited by 28
Xu, K., Dai, X., Wu, J., & Wen, K. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04093-z · Cited by 27 · cited 5×
“Overexpression of IMP2 enhances glucose uptake, lactate production, and extracellular acidification rate—hallmarks of increased glycolysis [109].”
InfluentialLu, Y., Qie, D., Yang, F., & Wu, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110467 · Cited by 27
Ouyang, J., Li, J., Li, D., Jiang, J., Hao, T., Xia, Y., Lu, X., Zhang, C., & He, Y. (2022) · Cancers · doi:10.3390/cancers14215381 · Cited by 27
Wu, H., Ding, X., Hu, X., Zhao, Q., Chen, Q., Sun, T., Li, Y., Guo, H., Li, M., Gao, Z., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02189-x · Cited by 26 · cited 2×
“In cancer, the long noncoding RNA, LINC021 , binds to IMP2 to enhance the stability of m6A-modi fi ed transcripts such as MSX1 and JARID2 [51].”
Micro RNA Let‐7b inhibits keratinocyte migration in cutaneous wound healing by targeting IGF 2 BP 2
Wu, Y., Zhong, J. L., Hou, N., Sun, Y., Ma, B., Nisar, M. F., Teng, Y., Tan, Z., Chen, K., Wang, Y., et al. (2017) · Experimental Dermatology · doi:10.1111/exd.13164 · Cited by 25 · cited 1×
“…as well as keratinocyte migration demonstrating the extensive regulatory This regulation alters epithelial–mesenchymal transition markers, including decreased vimentin and increased E-cadherin, and suppresses tumor growth and microvessel density in vivo. network controlling its activity [55–61].”
Zhou, L., Li, H., Cai, H., Liu, W., Pan, E., Yu, D., & He, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.809589 · Cited by 24 · cited 4×
“Additionally, high IMP2 expression is associated with immune suppression in oral cancer, reducing the number of CD8+ T cells in the tumor microenvironment [110].”
InfluentialLin, C.-W., Yang, W.-E., Su, C.-W., Lu, H.-J., Su, S.-C., & Yang, S.-F. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.91786 · Cited by 24 · cited 3×
“■ IMP2stabilizedEREG,promotingEMT[108].”
InfluentialShi, R., Zhao, R., Shen, Y., Wei, S., Zhang, T., Zhang, J., Shu, W., Cheng, S., Teng, H., & Wang, H. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00781-9 · Cited by 24 · cited 5×
“In endometrial cancer (EC), circCHD7 , a circular RNA upregulated in tumor tissues, interacts with IMP2 to stabilize the mRNA of platelet-derived growth factor receptor beta (PDGFRB) [28].”
InfluentialReading the m6A-encoded epitranscriptomic information in development and diseases
Chen, Y., Zhou, Z., Chen, Y., & Chen, D. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01293-7 · Cited by 24 · cited 1×
“Phylogenetically conserved RRM domains on readers are responsible for IMP2 identifying m6A marks on RNA [17,27].”
Waly, A. A., El-Ekiaby, N., Assal, R. A., Abdelrahman, M. M., Hosny, K. A., El Tayebi, H. M., Esmat, G., Breuhahn, K., & Abdelaziz, A. I. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2018.01918 · Cited by 23 · cited 1×
“…as well as keratinocyte migration demonstrating the extensive regulatory This regulation alters epithelial–mesenchymal transition markers, including decreased vimentin and increased E-cadherin, and suppresses tumor growth and microvessel density in vivo. network controlling its activity [55–61].”
Yi, J., Peng, F., Zhao, J., & Gong, X. (2023) · Scientific Reports · doi:10.1038/s41598-023-44379-x · Cited by 21
Czepukojc, B., Abuhaliema, A., Barghash, A., Tierling, S., Naß, N., Simon, Y., Körbel, C., Cadenas, C., van Hul, N., Sachinidis, A., et al. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00179 · Cited by 20 · cited 2×
“Transgenic overexpression of IMP2 in mice using the liver-specific promoter LAP caused improved glucose tolerance, a buildup of liver fat, and cirrhosis [65–67].”
Wu, T., Liao, L., Wu, T., Chen, S., Yi, Q., & Xu, M. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2283328 · Cited by 20 · cited 2×
“In vivo xenograft models demonstrated that CDC45 depletion significantly reduces tumor growth, underscoring the critical role of the IMP2-CDC45 axis in driving HCC progression [115].”
Alvarez‐Dominguez, J. R., Winther, S., Hansen, J. B., Lodish, H. F., & Knoll, M. (2021) · iScience · doi:10.1016/j.isci.2021.103680 · Cited by 20 · cited 1×
“Another example is lncRAP2 , a conserved cytoplasmic lncRNA enriched in adipose tissue [50]. lncRAP2 directly binds to IMP2, forming a complex that stabilizes target mRNAs encoding key regulators of adipogenesis and energy metabolism, such as adiponectin.”
The RNA-Binding Protein IMP2 Drives a Stromal-Th17 Cell Circuit in Autoimmune Neuroinflammation
Bechara, R., Amatya, N., Majumder, S., Zhou, C., Li, Y., Liu, Q., McGeachy, M. J., & Gaffen, S. L. (2022) · JCI Insight · doi:10.1172/jci.insight.152766 · Cited by 18 · cited 1×
“IMP2 promotes inflammatory responses in several autoimmune conditions, including autoimmune neuroinflammation and autoimmune glomerulonephritis (AGN), working in conjunction with cytokines like IL-17 and TNF α [118].”
Sa, R., Liang, R., Qiu, X., He, Z., Liu, Z., & Chen, L. (2022) · Cancers · doi:10.3390/cancers14051268 · Cited by 18
Wu, S., Chi, C., Weng, S., Zhou, W., & Liu, Z. (2023) · Apoptosis · doi:10.1007/s10495-023-01846-0 · Cited by 18 · cited 3×
“IMP2 supports glycolytic functions in FLT3-ITD-positive acute myeloid leukemia (AML), a common and aggressive form of AML characterized by an internal tandem duplication mutation in the FLT3 gene [101].”
InfluentialDeng, H., Yao, H., Zhou, S., He, C., Huang, Y., Li, Y., Chen, H., & Shu, J. (2023) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2023.101948 · Cited by 16
EIF4A3 ‐Induced CircDHTKD1 regulates glycolysis in non‐small cell lung cancer via stabilizing PFKL
Liu, Z., Li, W., Wang, Z., Yang, Q., Chen, L., Chen, W., & Qu, X. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18465 · Cited by 14 · cited 3×
“IMP2 promotes glycolysis and tumor growth in non-small cell lung cancer (NSCLC) by stabilizing the mRNA of the glycolytic enzyme PFKL. CircDHTKD1 , a circular RNA, binds to IMP2, which in turn binds to PFKL , preventing its degradation [106].”
InfluentialMashayekhi, V., Schomisch, A., Rasheed, S., Aparicio-Puerta, E., Risch, T., Yildiz, D., Koch, M., Both, S., Ludwig, N., Legroux, T. M., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01701-y · Cited by 14 · cited 1×
“In colorectal malignancies, IMP2 is a key regulator of tumor-associated macrophages (TAMs) by influencing the cargo of extracellular vesicles (EVs) released by cancer cells [122].”
Almawi, W. Y., Zidi, S., Sghaier, I., El-Ghali, R. M., Daldoul, A., & Midlenko, A. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2022.12.017 · Cited by 13 · cited 1×
“Single nucleotide polymorphism variants in the IGF2BP2 gene have been associated with the incidence of breast cancer, including triple negative breast cancer (TNBC), with higher IMP2 protein expression consistent with an oncogenic role [98].”
Li, Y., Xiao, Z., Wang, Y., Zhang, D., & Chen, Z. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03349-7 · Cited by 13
Regué, L., Wang, W., Ji, F., Avruch, J., Wang, H., & Dai, N. (2023) · Diabetes · doi:10.2337/db21-1087 · Cited by 12 · cited 3×
“IMP2 promotes the commitment of mesenchymal stem cells (MSCs) to the adipogenic lineage [39]. in adipocyte precursors, affecting their differentiation potential.”
Cui, Y., Wen, Y. C., Lv, C., Zhao, D., Yang, Y. P., Qiu, H., & Wang, C. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12802 · Cited by 12 · cited 1×
“In B-cell lymphoma, IMP2 acts upon the cell cycle and regulates proliferation by binding to and stabilizing NT5DC2 , which is involved in the metabolism of nucleotides by hydrolysis and is implicated in the progression of cancer [103].”
Ren, J., Huang, B., Li, W., Wang, Y., Pan, X., Ma, Q., Liu, Y., Wang, X., Liang, C., Zhang, Y., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101904 · Cited by 11 · cited 3×
“Conversely, knockdown of IMP2 reduces CKB levels, which correlates with increased metastatic potential in xenograft models [111].”
InfluentialTang, X., Tang, Q., Li, S., Li, M., & Yang, T. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01669-7 · Cited by 10
Qiu, C., Wang, X., Batson, S. A., Wang, B., Casiano, C. A., Francia, G., & Zhang, J.-Y. (2023) · Cancers · doi:10.3390/cancers15164064 · Cited by 9 · cited 1×
“IGF2BP2 mRNA and protein are frequently overexpressed across a wide variety of cancer types, as exemplified by proposals for IMP2 expression to be used as a predictive biomarker in prostate cancer as part of a panel of tumor-associated antigens [80].”
Fu, D., Shi, X., Yi, X., Wu, D., He, H., Zhou, W., & Cheng, W. (2024) · BMC Urology · doi:10.1186/s12894-024-01534-4 · Cited by 9
Chanda, S., Lepikhov, K., Dahlem, C., Schymik, H. S., Hoppstädter, J., Geber, A.-K., Wagner, K., Kessler, S. M., Empting, M., & Kiemer, A. K. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2901041 · Cited by 8 · cited 3×
“Homozygous IGF2BP2 knockout in lung cells led to a complete halt of proliferation [85].”
O’Reilly, M. E., Ho, S., Coronel, J., Zhu, L., Liu, W., Xue, C., Kim, E., Cynn, E., Matias, C. V., Soni, R. K., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114240 · Cited by 7 · cited 1×
“…PDGFR α promoter-regulated IMP2 deletion in MSCs (PIMP2-KO) showed resistance to diet-induced obesity. for stabilizing the mRNAs of IL-8 and KLF5 —key genes involved in adipogenesis—upon linc-ADAIN knockdown in This e ff ect is a tt ributed to IMP2 regulation of glycolytic human adipocytes [62].”
Zhao, J., Wu, Y., Yue, Y., Chen, M., Xu, Y., Liu, X., Liu, X., Gao, X., Wang, H., Si, X., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14772 · Cited by 6 · cited 1×
“In patients with NSCLC treated with immune checkpoint inhibitors, IMP2 expression is correlated with longer progression-free survival, suggesting that it might function as a prognostic biomarker [116].”
(2023) · PubMed · Cited by 6
Structural insights into IMP2 dimerization and RNA binding
Zorc, S., Munoz-Tello, P., O'Leary, T., Yu, X., Nag, M., Hansel-Harris, A., Forli, S., Griffin, P. R., Kojetin, D. J., Roy, R. N., et al. (2024) · doi:10.1101/2024.02.16.580656 · Cited by 5 · cited 3×
“In this system, the RNA that IMP2 bound was likely unfolded; however, in full cellular systems, the folding conditions and RNA structural elements may vary [15].”
InfluentialVelmurugan, S., Deshmukh, V., Sontakke, B., Chandrasekaran, K., & Subbaraj, G. (2024) · World Academy of Sciences Journal · doi:10.3892/wasj.2024.292 · Cited by 5 · cited 1×
“The study also suggested a link between the rs1470579 variant and T2D under allelic and recessive models [74].”
Structural insights into IMP2 dimerization and RNA binding
Zorc, S. A., Munoz-Tello, P., O’Leary, T., Yu, X., Karadi Giridhar, M. N., Hondros, A. D., Hansel-Harris, A., Forli, S., Griffin, P. R., Kojetin, D. J., et al. (2025) · Journal of Structural Biology · doi:10.1016/j.jsb.2025.108247 · Cited by 5
A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors
Němejcová, K., Bártů, M. K., Michálková, R., Drozenová, J., Fabian, P., Fadare, O., Hausnerová, J., Laco, J., Matěj, R., Méhes, G., et al. (2023) · Diagnostic Pathology · doi:10.1186/s13000-023-01300-4 · Cited by 4 · cited 1×
“…for CTGF expression of IMP1, IMP2, and IMP3, revealed that IMP2 was expressed in over 5% of all tumor types analyzed, the highest levels observed in the micropapil-lary variant of serous borderline tumors and high-grade serous carcinoma (HGSCs), where expression ranged from 98 to 100% [117].”
Cited by
Li, L., Cui, Y., Ji, Y., Ma, K., Lin, X., Liu, T., Sun, J., Liu, H., Guo, J., & Li, M. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06093-5 · Cited by 4
“Insulin-like growth factor 2 mRNA-binding protein 2 (IMP2/IGF2BP2), a key reader in the m 6 A process, is abnormally expressed in T2DM, obesity and cancer [15].”
Co-expression network analysis reveals repression of Igf2bp2 by REV-ERBβ in skeletal musclePreprint
Vishnu, A. M., Zhang, Q., Srivastava, S., Koronowski, K. B., & Srivastava, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.13.724827
Profibrotic macrophage populations and cell communications in pulmonary fibrosis
Zhang, D., Zhao, W., Xu, C., Du, L., & Liu, Q. (2026) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-026-01179-x
Metadata
- Authors
- Das, J., Busia-Bourdain, O., Khan, K. M., & Wolfe, A. L.
- Affiliations
- The Graduate Center, CUNY (US)
- City University of New York (US)
- Corresponding author
- Wolfe, Andrew L.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2025-03-07
- Volume
- 26
- Issue
- 6
- Pages
- 2415
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11942581
- OpenAlex
- W4408226515
- Semantic Scholar
- e40a3ca7c770e56d3fa51c842186504c3aa272f2
- Cited by
- 3
- References
- 154
- Citations by year
- 2026: 3
- FWCI
- 0.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (U54CA221704, R00CA226363, 2318923, ENHC55171)
- Hunter College of the City University of New York (U54CA221704, R00CA226363, 2318923, ENHC55171)
- National Science Foundation (U54CA221704, R00CA226363, 2318923, ENHC55171)
- PSC-CUNY Research (U54CA221704, R00CA226363, 2318923, ENHC55171)
- Oncogenuity, Inc. (U54CA221704, R00CA226363, 2318923, ENHC55171)
- DASNY GRTI (U54CA221704, R00CA226363, 2318923, ENHC55171)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- IGF2BP2, RNA-binding proteins, m6A RNA methylation, RNA metabolism, cancer, metabolic disorders, diabetes mellitus, obesity, adipose tissue, gene amplification, carcinogenesis, tumor immune evasion, macrophage polarization, inflammation, therapeutic target
- MeSH terms
- Animals, Humans, Neoplasms, RNA, RNA-Binding Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.